Table 2.
Mixed effects models of receipt of evidence-based treatments.
| Chemotherapy | Brachytherapy | |
|---|---|---|
| Annualized hospital volume | 1.003 (0.998-1.008) | 1.026 (1.013-1.039)* |
| Year of diagnosis | ||
| 1998 | Referent | Referent |
| 1999 | 1.90 (1.70- 2.11)** | 0.91 (0.83- 1.01) |
| 2000 | 1.99 (1.78- 2.21)** | 0.88 (0.79- 0.98)* |
| 2001 | 2.01 (1.80- 2.24)** | 0.80 (0.72- 0.89)** |
| 2002 | 1.98 (1.75- 2.25)** | 0.33 (0.27- 0.40)** |
| 2003 | 2.05 (1.85- 2.26)** | 0.80 (0.72- 0.88)** |
| 2004 | 2.05 (1.85- 2.27)** | 0.80 (0.73- 0.89)** |
| 2005 | 2.10 (1.90- 2.32)** | 0.83 (0.75- 0.91)* |
| 2006 | 2.16 (1.95- 2.38)** | 0.82 (0.74- 0.90)* |
| 2007 | 2.11 (1.91- 2.33)** | 0.83 (0.75- 0.91)* |
| 2008 | 2.15 (1.95- 2.38)** | 0.85 (0.77- 0.93)* |
| 2009 | 2.18 (1.98- 2.41)** | 0.89 (0.81- 0.98)* |
| 2010 | 2.20 (2.00- 2.43)** | 0.86 (0.78- 0.94)* |
| 2011 | 2.16 (1.95- 2.38)** | 0.86 (0.78- 0.95)* |
| Age | ||
| <40 | Referent | Referent |
| 40-49 | 0.99 (0.94- 1.03) | 0.96 (0.91- 1.02) |
| 50-59 | 0.96 (0.92- 1.01) | 0.94 (0.89- 0.99)* |
| 60-69 | 0.94 (0.89- 0.99)* | 0.94 (0.88- 1.01) |
| ≥70 | 0.67 (0.62- 0.72)** | 0.77 (0.71- 0.84)** |
| Race | ||
| White | Referent | Referent |
| Black | 0.97 (0.93- 1.01) | 0.97 (0.92- 1.02) |
| Hispanic | 1.02 (0.97- 1.07) | 1.02 (0.96- 1.09) |
| Other | 1.02 (0.95- 1.10) | 1.04 (0.95- 1.13) |
| Unknown | 0.98 (0.84- 1.15) | 0.97 (0.80- 1.18) |
| Insurance status | ||
| Commercial | Referent | Referent |
| Medicare | 0.93 (0.88- 0.98)* | 0.92 (0.86- 0.98)* |
| Medicaid | 0.96 (0.92- 1.00) | 0.92 (0.88- 0.97)* |
| Uninsured | 0.98 (0.94- 1.03) | 0.91 (0.85- 0.96)* |
| Other | 0.98 (0.85- 1.14) | 0.99 (0.83- 1.17) |
| Unknown | 0.95 (0.88- 1.04) | 0.83 (0.74- 0.93)* |
| Region | ||
| Northeast | Referent | Referent |
| Midwest | 1.01 (0.96- 1.05) | 0.99 (0.91- 1.08) |
| South | 0.96 (0.92- 1.00) | 0.92 (0.85- 1.00) |
| West | 1.00 (0.95- 1.05) | 0.83 (0.75- 0.92)* |
| Location | ||
| Metro | Referent | Referent |
| Urban | 0.99 (0.95- 1.04) | 1.01 (0.95- 1.07) |
| Rural | 1.02 (0.91- 1.15) | 1.11 (0.97- 1.28) |
| Unknown | 1.01 (0.95- 1.09) | 1.03 (0.95- 1.13) |
| Hospital type | ||
| Community cancer program | Referent | Referent |
| Academic | 1.01 (0.97- 1.04) | 1.03 (0.96- 1.11) |
| Other | 0.93 (0.81- 1.06) | 0.97 (0.82- 1.14) |
| Histology | ||
| Squamous | Referent | Referent |
| Adenocarcinoma | 0.98 (0.93- 1.04) | 0.91 (0.85- 0.98)* |
| Adenosquamous | 1.02 (0.93- 1.12) | 1.03 (0.92- 1.14) |
| Other | 0.98 (0.93- 1.05) | 0.91 (0.85- 0.99)* |
| Grade | ||
| 1 | Referent | Referent |
| 2 | 0.99 (0.92- 1.08) | 0.97 (0.89- 1.07) |
| 3 | 0.99 (0.92- 1.07) | 0.94 (0.86- 1.04) |
| Unknown | 0.99 (0.91- 1.07) | 0.97 (0.88- 1.06) |
| Stage | ||
| IIB | Referent | Referent |
| IIIA | 0.98 (0.90- 1.06) | 0.82 (0.74- 0.91)* |
| IIIB | 1.02 (0.98- 1.05) | 0.83 (0.80- 0.87)** |
| IVA | 0.98 (0.92- 1.04) | 0.45 (0.41- 0.49)** |
| Brachytherapy | ||
| No | Referent | - |
| Yes | 1.10 (1.07- 1.14)** | - |
| Chemotherapy | ||
| No | - | Referent |
| Yes | - | 1.29 (1.22- 1.36)** |
| Unknown | - | 0.92 (0.75- 1.14) |
Risk ratio (95% confidence interval).
*
P<0.05,
**
P<0.0001